Digital health player Akili has raised $110 million fourth-round funding, backed by a number of pharma groups, as it works towards extending its product range beyond its flagship EndeavorRx app.

The study is being conducted by Japanese drugmaker Shionogi, which formed a strategic partnership with Akili in 2019 to bring digital therapeutics (DTx) to Asian markets. The ADHD app – renamed ...